Drugs / Recombinant Respiratory Syncytial Virus Vaccine(CHO cell) (Single adjuvant)
Recombinant Respiratory Syncytial Virus Vaccine(CHO cell) (Single adjuvant)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07582796 | May 2026 → Sep 2027 expected | respiratory syncytial virus infectious disease | Ab&B Bio-tech Co., Ltd.JS | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Respiratory Syncytial Virus Vaccine(CHO cell) (Single adjuvant) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07582796 ↗ |
| Modality | Vaccine | “Recombinant Respiratory Syncytial Virus Vaccine(CHO cell) (Single adjuvant)” NCT07582796 ↗ |
| Route | Intramuscular | “The vaccine is administered as a single 0.25 mL intramuscular injection into the deltoid muscle of the upper arm on Day 0.” NCT07582796 ↗ |